CH683672A5 - Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe. - Google Patents

Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe. Download PDF

Info

Publication number: CH683672A5
Authority: CH; Switzerland
Prior art keywords: water; soluble; solid solution; monoesters; monoester
Prior art date: 1987-09-15

Application number

CH3398/88A

Other languages

German (de)

English (en)

Inventor

Lorenz Hahn

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-15

Filing date

1988-09-12

Publication date

1994-04-29

1988-09-12 Application filed by Sandoz Ag filed Critical Sandoz Ag

1994-04-29 Publication of CH683672A5 publication Critical patent/CH683672A5/de

Links

239000002904 solvent Substances 0.000 title claims description 30
239000000546 pharmaceutical excipient Substances 0.000 title claims description 5
229940124531 pharmaceutical excipient Drugs 0.000 title description 2
239000008177 pharmaceutical agent Substances 0.000 title 1
239000006104 solid solution Substances 0.000 claims abstract description 50
229930182912 cyclosporin Natural products 0.000 claims abstract description 22
108010036941 Cyclosporins Proteins 0.000 claims abstract description 14
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 14
229930195729 fatty acid Natural products 0.000 claims abstract description 14
239000000194 fatty acid Substances 0.000 claims abstract description 14
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
229920001184 polypeptide Polymers 0.000 claims abstract description 13
150000004665 fatty acids Chemical class 0.000 claims abstract description 11
229920006395 saturated elastomer Polymers 0.000 claims abstract description 11
229920005862 polyol Polymers 0.000 claims abstract description 9
150000003077 polyols Chemical class 0.000 claims abstract description 9
150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
239000000243 solution Substances 0.000 claims description 51
239000004480 active ingredient Substances 0.000 claims description 48
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 20
229940032085 sucrose monolaurate Drugs 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 12
239000012736 aqueous medium Substances 0.000 claims description 10
230000000144 pharmacologic effect Effects 0.000 claims description 10
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 8
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000006193 liquid solution Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000001816 cooling Methods 0.000 claims description 3
238000002844 melting Methods 0.000 claims description 3
230000008018 melting Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000008186 active pharmaceutical agent Substances 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 37
150000001875 compounds Chemical class 0.000 abstract description 11
-1 such polypeptides Chemical class 0.000 abstract description 11
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 51
108010036949 Cyclosporine Proteins 0.000 description 51
229960001265 ciclosporin Drugs 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
229930006000 Sucrose Natural products 0.000 description 15
239000005720 sucrose Substances 0.000 description 15
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
239000013543 active substance Substances 0.000 description 12
229930105110 Cyclosporin A Natural products 0.000 description 10
238000001704 evaporation Methods 0.000 description 9
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
239000002253 acid Substances 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 5
229940063122 sandimmune Drugs 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
229960002466 proquazone Drugs 0.000 description 4
230000003381 solubilizing effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
108010069514 Cyclic Peptides Proteins 0.000 description 3
102000001189 Cyclic Peptides Human genes 0.000 description 3
XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000036765 blood level Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000002141 anti-parasite Effects 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
150000004043 trisaccharides Chemical class 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 1
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
229940114072 12-hydroxystearic acid Drugs 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
KSEBMYQBYZTDHS-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241001340526 Chrysoclista linneella Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920001076 Cutan Polymers 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
150000001545 azulenes Chemical class 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
108010040781 dihydrocyclosporin D Proteins 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005313 fatty acid group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003165 hydrotropic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical group 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229960004958 ketotifen Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
231100000927 organotoxic Toxicity 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
229960003656 ricinoleic acid Drugs 0.000 description 1
FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
239000001570 sorbitan monopalmitate Substances 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
229950004959 sorbitan oleate Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940035023 sucrose monostearate Drugs 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000012982 x-ray structure analysis Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CH3398/88A 1987-09-15 1988-09-12 Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe. CH683672A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3730909		1987-09-15
DE3802355		1988-01-27

Publications (1)

Publication Number	Publication Date
CH683672A5 true CH683672A5 (de)	1994-04-29

Family

ID=25859774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3398/88A CH683672A5 (de)	1987-09-15	1988-09-12	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe.

Country Status (24)

Country	Link
JP (1)	JP3090666B2 (da)
KR (1)	KR0131084B1 (da)
AT (1)	AT395819B (da)
AU (1)	AU628787B2 (da)
BE (1)	BE1001204A5 (da)
CA (1)	CA1338775C (da)
CH (1)	CH683672A5 (da)
DK (1)	DK175132B1 (da)
ES (1)	ES2012118A6 (da)
FI (1)	FI94837C (da)
FR (1)	FR2620336B1 (da)
GB (1)	GB2209671B (da)
GR (1)	GR1002243B (da)
HU (1)	HU205010B (da)
IE (1)	IE61195B1 (da)
IL (1)	IL87746A (da)
IT (1)	IT1224886B (da)
LU (1)	LU87335A1 (da)
MY (1)	MY103769A (da)
NL (1)	NL195094C (da)
NO (1)	NO179434C (da)
NZ (1)	NZ226163A (da)
PT (1)	PT88492B (da)
SE (1)	SE503279C2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) *	1989-01-28	1992-07-30	Sandoz Ag	Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) *	1989-02-09	1991-10-22	Sandoz Sa	Nouvelles compositions pharmaceutiques a base de cyclosporines.
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
DK1033128T4 (da)	1993-09-28	2012-03-19	Scherer Gmbh R P	Blød gelatinekapselfremstilling
ATE218359T1 (de)	1994-11-03	2002-06-15	Novartis Erfind Verwalt Gmbh	Neue zubereitungsformen des cyclosporins zur oralen applikation mit einfacher zusammensetzung und hoher bioverfügbarkeit und verfahren zu deren herstellung
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
TW414696B (en) *	1996-07-01	2000-12-11	Mitsubishi Kagaku Foods Kk	Anti-bacteria agent
PT988046E (pt)	1997-01-30	2004-12-31	Novartis Ag	Composicoes farmaceuticas sem oleo contendo ciclosporina a
GB2326337A (en) *	1997-06-20	1998-12-23	Phares Pharma Holland	Homogeneous lipid compositions for drug delivery
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
AU2003267747A1 (en) *	2003-10-14	2005-05-05	Ramesh Varada Bapat	Sterile gelling agents
JP5422871B2 (ja) *	2006-10-24	2014-02-19	不二製油株式会社	イソフラボン類組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL284933A (da) *	1961-10-31
GB1134878A (en) *	1966-05-12	1968-11-27	Suga Kazuo	Improvements in and relating to oryzanol solutions and compositions
FR5986M (da) *	1966-11-22	1968-06-21
BE787842A (fr) *	1971-08-25	1972-12-18	Sumito Chemical Cy Ltd	Procede de preparation d'une suspension aqueuse de cristaux stables du type non beta d'esters d'acides gras superieurs du chloramphenicol
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
JPS57128634A (en) *	1981-02-03	1982-08-10	Eisai Co Ltd	Elastase-containing compound increasing absorption
EP0179583A1 (en) *	1984-10-04	1986-04-30	Merck & Co. Inc.	A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤

1988
- 1988-09-01 HU HU884518A patent/HU205010B/hu unknown
- 1988-09-12 BE BE8801044A patent/BE1001204A5/fr not_active IP Right Cessation
- 1988-09-12 CH CH3398/88A patent/CH683672A5/de not_active IP Right Cessation
- 1988-09-12 LU LU87335A patent/LU87335A1/xx unknown
- 1988-09-12 FR FR888811953A patent/FR2620336B1/fr not_active Expired - Lifetime
- 1988-09-13 SE SE8803221A patent/SE503279C2/sv not_active IP Right Cessation
- 1988-09-13 AU AU22172/88A patent/AU628787B2/en not_active Expired
- 1988-09-13 PT PT88492A patent/PT88492B/pt not_active IP Right Cessation
- 1988-09-13 FI FI884192A patent/FI94837C/fi not_active IP Right Cessation
- 1988-09-13 GB GB8821443A patent/GB2209671B/en not_active Expired - Lifetime
- 1988-09-13 IE IE277288A patent/IE61195B1/en not_active IP Right Cessation
- 1988-09-13 NZ NZ226163A patent/NZ226163A/xx unknown
- 1988-09-13 CA CA000577214A patent/CA1338775C/en not_active Expired - Lifetime
- 1988-09-13 NO NO884052A patent/NO179434C/no not_active IP Right Cessation
- 1988-09-14 KR KR1019880011874A patent/KR0131084B1/ko not_active Expired - Lifetime
- 1988-09-14 MY MYPI88001027A patent/MY103769A/en unknown
- 1988-09-14 GR GR880100602A patent/GR1002243B/el not_active IP Right Cessation
- 1988-09-14 IL IL87746A patent/IL87746A/xx active Protection Beyond IP Right Term
- 1988-09-14 AT AT0224988A patent/AT395819B/de not_active IP Right Cessation
- 1988-09-14 JP JP63231396A patent/JP3090666B2/ja not_active Expired - Lifetime
- 1988-09-14 IT IT8848349A patent/IT1224886B/it active
- 1988-09-14 DK DK198805111A patent/DK175132B1/da not_active IP Right Cessation
- 1988-09-15 ES ES8802831A patent/ES2012118A6/es not_active Expired - Lifetime
- 1988-09-15 NL NL8802275A patent/NL195094C/nl not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP3090666B2 (ja)	2000-09-25
IT1224886B (it)	1990-10-24
PT88492A (pt)	1988-10-01
LU87335A1 (fr)	1989-04-06
FR2620336A1 (fr)	1989-03-17
SE8803221L (sv)	1989-03-16
NL195094C (nl)	2003-12-17
SE8803221D0 (sv)	1988-09-13
NO179434B (no)	1996-07-01
DK175132B1 (da)	2004-06-14
NO884052L (no)	1989-03-16
HUT49494A (en)	1989-10-30
ES2012118A6 (es)	1990-03-01
SE503279C2 (sv)	1996-05-13
FR2620336B1 (fr)	1991-10-25
FI94837B (fi)	1995-07-31
FI884192A0 (fi)	1988-09-13
FI884192L (fi)	1989-03-16
IT8848349A0 (it)	1988-09-14
KR0131084B1 (ko)	1998-04-17
HU205010B (en)	1992-03-30
FI94837C (fi)	1995-11-10
AT395819B (de)	1993-03-25
GB8821443D0 (en)	1988-10-12
NO884052D0 (no)	1988-09-13
CA1338775C (en)	1996-12-10
GB2209671B (en)	1991-11-13
IE882772L (en)	1989-03-15
BE1001204A5 (fr)	1989-08-16
GR880100602A (el)	1989-06-22
KR890004694A (ko)	1989-05-09
PT88492B (pt)	1993-03-31
NO179434C (no)	1996-10-09
MY103769A (en)	1993-09-30
GB2209671A (en)	1989-05-24
GR1002243B (en)	1996-04-22
AU2217288A (en)	1989-04-27
IL87746A (en)	1992-07-15
IL87746A0 (en)	1989-02-28
NL8802275A (nl)	1989-04-03
IE61195B1 (en)	1994-10-19
DK511188A (da)	1989-03-16
ATA224988A (de)	1992-08-15
JPH01151526A (ja)	1989-06-14
AU628787B2 (en)	1992-09-24
DK511188D0 (da)	1988-09-14
NZ226163A (en)	1991-08-27

Legal Events

Date	Code	Title	Description
1997-05-15	PFA	Name/firm changed	Owner name: SANDOZ AG TRANSFER- NOVARTIS AG
2008-09-15	PL	Patent ceased

Publication	Publication Date	Title
AT395819B (de)	1993-03-25	Wasserloesliche monoester als solubilisatoren fuer pharmakologische wirkstoffe und pharmazeutische hilfsstoffe
DE69721729T2 (de)	2003-12-11	[3'-DESOXY-3-OXO-MeBmt]1-[Val]2-CICLOSPORIN ENTHALTENDE ARZNEIMITTELEMULSION
AT404552B (de)	1998-12-28	Neue cyclosporin enthaltende galenische formulierungen
DE69635720T2 (de)	2006-08-10	Pharmazeutische Zusammensetzungen von Cyclosporine mit einer Polyethoxylierten hydroxy-fettsäure
AT397914B (de)	1994-08-25	Pharmazeutisches präparat für die intravenöse wirkstoffapplikation mit hydrosolen im nanometerbereich
DE3924207C2 (da)	1992-07-09
DE4340781C2 (de)	1995-11-09	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
DE60114145T3 (de)	2015-09-17	Fulvestrant formulierung
DE69325256T2 (de)	1999-12-16	Insizierbare lecithin gel
AT403163B (de)	1997-11-25	Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
DE4005190A1 (de)	1990-08-23	Neue cyclosporinhaltige galenische formen
DE3930928A1 (de)	1990-03-22	Cyclosporin enthaltende pharmazeutische formulierungen
DE69822814T2 (de)	2005-01-27	Zusammensetzung enthaltend Cyclosporin in einem hydrophilen Träger
DE68903814T2 (de)	1993-04-08	Etoposid-loesungen.
DE60018715T2 (de)	2006-04-27	Pharmazeutische Zusammensetzung enthaltend Cyclosprin als aktiven Bestandteil
DE3830494B4 (de)	2006-05-18	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
EP2142169B1 (de)	2011-10-26	Wässrige pharmazeutische zubereitung
WO2017015690A1 (de)	2017-02-02	Konzentrat enthaltend alprostadil
DD283404A5 (de)	1990-10-10	Verfahren zur herstellung von ciclosporin in nichtsolvatisiertr orthonombischer kristallform